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Rheumatic fever (RF) and rheumatic heart disease (RHD) are 
primarily diseases of childhood and young adulthood. As a 
result of this epidemiological pattern, RF and RHD negatively 
impact on society by decreasing the capacity of the most 
productive age groups, as well as limiting future capacity by 
thwarting the development of young people. Acute RF and 
RHD lead to increased school absenteeism and drop-out, and 
lost wages due to parental absenteeism from work. The patient 
and the family bear most of the brunt of these costs, which are 
shared to some extent by society as a whole. 
The global burden of RF and RHD over the past century 
has shifted to fall almost entirely on people living in 
the developing world, who constitute 80% of the world 
population. The worldwide prevalence of RHD is estimated at 
15.6 million, with 282 000 new cases arising each year, resulting 
in 233 000 deaths per year.1 Ninety-five per cent of these cases 
and deaths occur in the developing world. Sub-Saharan Africa 
has the highest average prevalence of RHD of 30 per 1 000 
schoolchildren, leading to the designation of this region as 
the ‘hotspot’ of RF and RHD in the world.2 This geographical 
distribution of disease highlights the link of RF and RHD with 
poverty. RF and RHD are not only the result of conditions 
that exist in poverty; they also act to perpetuate poverty by 
crippling a significant proportion of the most productive 
members of society, thereby hindering economic growth. 
Understanding and defining the relationship between RF/
RHD and poverty is an important step in building the political 
support, national and international, to fashion and implement 
a plan of action to combat the disease.
What is the socio-economic impact of 
RF and RHD?
At least two studies from Brazil and India have attempted 
to quantify the socio-economic impact of RF and RHD.3,4 
The Brazilian study provides a useful breakdown of 
direct and indirect costs that impact on the patient, family 
and society.3 Direct costs to the family include medical 
consultations, laboratory tests, transportation, and lost wages. 
Assuming that most patients with RF/RHD receive publicly 
funded health care, direct costs to society include medical 
consultations not paid for by the family, hospital admissions, 
cardiac catheterisation and surgical costs, and medications 
and laboratory tests. Indirect costs to the family include 
lost wages because of work missed, while indirect costs to 
society encompass the production losses attributable to lost 
workdays. While these costs associated with RF and RHD are 
not exhaustive, they include most of the pertinent tangible 
costs. In Sao Paulo, Brazil, RF costs the affected patient and 
family about US$97/patient/year, and the disease costs 
society US$320/patient/year. The annual cost of a secondary 
prevention programme is US$23/patient/year in Brazil. 
Compared with the cost burden on the family or the society 
for treating a case of RF, this analysis clearly confirms that 
secondary prevention is a cost-effective intervention. 
The Indian study sets out to compare the cost-effectiveness 
of primary, secondary and tertiary prevention programmes 
for RF/RHD.4 The investigators compared the input cost vs. 
the output cost for each form of prevention strategy. They 
found that primary and secondary prevention are both cost-
effective interventions and while primary prevention is more 
expensive to implement, the outputs, or economic/social gains, 
of primary prevention exceed both secondary and tertiary 
gains. They also found that tertiary prevention (i.e. medical 
and surgical intervention for heart failure due to RHD) is 
least cost-effective. While this study has been criticised on 
methodological grounds,5 it highlights the fact that leaving the 
disease untreated increases the economic cost to the patient, 
family and society.
In addition to tangible economic losses associated with 
RF/RHD, there are also intangible costs, or social implications 
that cannot be quantified. Patients disabled by RHD often face 
physical limitations, which can restrict their future educational 
and work opportunities. The Brazilian study found that 
children affected by RF/RHD have a 22% school failure rate, 
which can further limit future career options. And with respect 
to their parents, 5% reported losing their jobs because of 
absenteeism associated with the illness of their child. 
What are the prospects for the 
eradication of RF and RHD?
The developing world faces a double burden of infectious 
diseases, which are associated with poverty, and chronic 
diseases associated with urbanisation and social change. RF 
and RHD comprise a unique disease entity that spans the 
infectious and post-infectious chronic disease paradigm. The 
antecedent stage of streptococcal pharyngitis is infectious, 
relatively simple to diagnose and inexpensive to treat.6 As 
the disease progresses towards the chronic stage (RHD), it 
becomes expensive for the patient, the family and the society to 
diagnose and to treat by medical and surgical means. 
It has been amply demonstrated in Cuba, Costa Rica and 
other countries that a comprehensive strategy of primary 
prevention (i.e. syndromic treatment of suspected ‘strep’ 
pharyngitis with penicillin), secondary prevention (screening 
for rheumatic heart disease in schoolchildren and use of 
penicillin prophylaxis for affected children), and tertiary 
prevention (i.e. medical and surgical treatment of patients 
with heart failure due to RHD) results in almost complete 
eradication of the disease within 10 - 20 years.7,8 
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The Drakensberg Declaration of the Pan African Society of 
Cardiology (PASCAR) calls on national ministries of health 
in Africa to adopt the A.S.A.P. Programme for the prevention 
of RF and RHD. This programme seeks to emulate the Cuban 
and Costa Rican examples through the application of evidence-
based approaches to the prevention of the disease on national 
and continental levels.9,10 The occasion of national Rheumatic 
Fever Week, which was marked by the Minister of Health on  
4 - 8 August 2008, provided us with an opportunity to 
rededicate ourselves to the fight for the eradication of RF and 
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Two articles1,2 published in this issue address male circumcision 
(MC).
Connolly et al.1 show in a national survey that MC, whether 
pre-pubertal or post-pubertal, has no protective effect 
on acquisition by males of HIV infection as measured by 
prevalence.
Sidler et al.2 state that neonatal MC continues to be promoted 
without adequate justification as a medicalised ritual, via an 
HIV prevention rationale. They caution that for MC to be a 
therapeutic as opposed to a non-therapeutic procedure, it is 
necessary to gather more corroborative and consistent evidence 
of its benefit, consider the potential harms (psychological, 
sexual, surgical and behavioural/disinhibition), examine the 
ethical implications, and examine effectiveness and efficiency 
(costs and benefits) at the population and societal levels. They 
point out that MC is not just a technical surgical intervention 
– it takes place in a social context that can radically alter 
the anticipated outcome. At the 2008 International AIDS 
Conference3 in Mexico cultural, political and educational issues 
raised by the intervention, such as decreased condom use and 
marginalisation of women, were hotly debated. Some cultural 
interpretations may view MC as a licence to have unprotected 
sex. A case in point is Swaziland, where men are flocking to 
be circumcised with the understanding that this means they 
no longer need to use other preventive methods (e.g. wear 
condoms or limit the number of sexual partners).4
The 2003 Cochrane review5 of observational studies of MC 
effectiveness  concluded that there was insufficient evidence 
to support it as an anti-HIV intervention. Three randomised 
controlled trials (RCTs) from South Africa, Kenya and Uganda 
in 2006 - 2007 show a protective effect of MC.  However, 
Garenne6 has subsequently shown from observational data that 
there is considerable heterogeneity of the effect of MC across 
14 African countries. Despite the South African RCT showing 
a protective effect, he reports for the nine South African 
provinces that ‘there is no evidence that HIV transmission 
over the period 1994 - 2004 was slower in those provinces with 
higher levels of circumcision’. Interestingly, in both Kenya 
and Uganda, where two of the RCTs were done, a protective 
effect of MC was observed, but a harmful effect was observed 
in Cameroon, Lesotho and Malawi. The other eight countries 
showed no significant effect of MC.
These somewhat discordant findings are difficult to interpret. 
While RCTs are theoretically strong designs, it is conceivable 
Rolling out male circumcision as a mass HIV/AIDS 
intervention seems neither justified nor practicable  
October 2008, Vol. 98, No. 10  SAMJ
EDITORIALS
pg780-782.indd   781 9/29/08   10:32:09 AM
782
that their findings are not generalisable beyond their settings.  
Furthermore, there have been no trials of neonatal MC. Study 
flaws such as inability to obtain double blinding, and loss 
to follow-up in RCTs,  may effectively degrade their quality 
to that of observational studies. Meanwhile other disturbing 
findings referred to by Sidler et al. are emerging, including the 
reported higher risk for women partners of circumcised HIV-
positive men, disinhibition, urological complications, relatively 
small effect sizes of MC at the population level, and relative 
cost-inefficiency of MC.
Not all objections to MC as an HIV intervention have to 
do with evidence of effectiveness or cost. Sidler et al. raise 
ethical objections. Owing to the current climate of desperation 
with regard to the HIV epidemic, evidence in favour of MC 
frequently seems overstated. This reduces the scope for 
informed consent and autonomy for adult men considering 
the procedure. Further problems arise in the case of neonates 
whose parents may be considering the procedure. Whereas 
informed consent is at least possible for adult men, it is 
clearly not possible for neonates. Parents can only guess what 
the child’s wishes would be if he were presented with the 
information they have at their disposal. If it could be shown 
that circumcision was necessary in the neonatal period, 
parental consent on behalf of the neonate would be justified. 
But since no valid surgical indications for circumcision exist 
in this period, and the future benefit to the child in respect of 
HIV avoidance is not relevant before sexual debut, the duty of 
parents may well be to err on the side of caution, and defer the 
procedure until the child can make an autonomous decision. 
In the absence of compelling indications, a procedure such as 
circumcision could also be seen as a violation of the child’s 
right to bodily integrity. Furthermore, the ethical principle of 
non-maleficence cannot be upheld as there are clear harms 
attached to this practice, to which Sidler et al. refer in their 
article. Lastly, at a societal level MC may be unjust insofar as it 
could compete for resources with more effective and less costly 
interventions7 and disadvantage women.
Despite a strong pro-circumcision lobby driven by 
enthusiasts who have been promoting MC as an (HIV) 
intervention for many years, and impatience expressed by 
protagonists about the long delay after the 2006 - 2007 RCT 
results and the UNAIDS/WHO policy recommendations8 
of  March 2007,  few mass campaigns have been launched in 
African countries.
Given the epidemiological uncertainties and the economic, 
cultural, ethical and logistical barriers, it seems neither justified 
nor practicable to roll out MC as a mass anti-HIV/AIDS 
intervention.
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